Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II docetaxel + pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma
jRCTs011210068Phase 2Active, not recruiting
- Sponsor
- MSD
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by MSD. Primary endpoint: overall response rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
pembrolizumabdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs011210068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011210068.